Enzootic abortion vaccine supply issues announced
Ceva Animal Health says it is treating the issue with the “utmost urgency”.
Ceva Animal Health has announced that there will be a gap in the supply of its enzootic abortion of ewes (EAE) vaccine Cevac Chlamydia between June and August.
The company has said the issue has been caused by a batch failure during the manufacturing process and that it deeply regrets any inconvenience caused.
Last year also saw a shortage of the vaccine in the UK, which Ceva Animal Health blamed on delays in the manufacturing and distribution process. The issue was resolved by September and the company again hopes that the vaccine will become available later in the year.
Roy Geary, Ceva Animal Health’s regional director for Northern Europe, said: “Our dedicated team is working closely with our partners to resolve the challenges and restore normal supply levels as soon as possible. The vaccine challenge is being treated with the utmost urgency, and we are actively exploring alternative options to speed up the supply chain for future batches of the vaccine.
“We anticipate that the issue in supply will be resolved, with some stock potentially available later in the season, however we recognise that for some farmers the supply will arrive too late for them to use.”
Until the vaccine becomes available again, Ceva Animal Health has recommended that veterinary surgeons look at alternative ways to help their clients protect their flocks.
Mr Geary added: “We are encouraging vets to explore alternative means of safeguarding the health of their clients’ flocks during this period. We recommend implementing robust biosecurity measures and adhering to existing vaccination protocols for other preventable diseases to ensure the overall wellbeing of livestock.
“We will provide vet practices and the wider industry with regular updates as we progress toward a resolution and return to normal supply levels.”
Image © Shutterstock
FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.
